ONDINE BIOMEDICAL INC. Financials Ondine Biomedical Inc.
Equities
OBI
CA68234M2058
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.8 GBX | +4.00% |
|
+15.56% | -10.86% |
| May. 08 | Hellenic Dynamics and Ondine Biomedical raise funds | AN |
| May. 03 | Ondine Biomedical shares rise on fundraise to advance Steriwave | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 184.6 | 65.39 | 36.22 | 36.22 | - |
| Enterprise Value (EV) 2 | 154.5 | 53.64 | 35.12 | 32.42 | 33.32 |
| P/E ratio | - | - | -1.6 x | -2.59 x | -3.13 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 71.9 x | 102 x | 30.6 x | 13.9 x | 10.7 x |
| EV / Revenue | 60.1 x | 84.1 x | 29.7 x | 12.5 x | 9.8 x |
| EV / EBITDA | -9.09 x | -2.93 x | -2.42 x | -1.4 x | -1.42 x |
| EV / FCF | -8.98 x | -3.22 x | -2.21 x | -1.19 x | - |
| FCF Yield | -11.1% | -31.1% | -45.2% | -84% | - |
| Price to Book | - | 5.78 x | 15.1 x | -2.67 x | 21.3 x |
| Nbr of stocks (in thousands) | 194,585 | 194,593 | 277,286 | 277,286 | - |
| Reference price 3 | 0.5550 | 0.2050 | 0.0750 | 0.0750 | 0.0750 |
| Announcement Date | 5/19/22 | 5/10/23 | - | - | - |
1GBP in Million2CAD in Million3GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.791 | 2.569 | 0.638 | 1.184 | 2.598 | 3.4 |
| EBITDA 1 | - | -17.01 | -18.3 | -14.51 | -23.11 | -23.5 |
| EBIT 1 | - | -17.52 | -18.76 | -14.99 | -23.62 | -24.1 |
| Operating Margin | - | -681.98% | -2,940.91% | -1,266.65% | -909.5% | -708.82% |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | - | - | - | -15.9 | -18.7 | -24.2 |
| Net margin | - | - | - | -1,343.47% | -719.92% | -711.76% |
| EPS 2 | - | - | - | -0.0470 | -0.0290 | -0.0240 |
| Free Cash Flow 1 | - | -17.21 | -16.66 | -15.88 | -27.22 | - |
| FCF margin | - | -670.07% | -2,610.66% | -1,342.15% | -1,047.97% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/7/21 | 5/19/22 | 5/10/23 | - | - | - |
1CAD in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 30.1 | 11.7 | 1.1 | 3.8 | 2.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -17.2 | -16.7 | -15.9 | -27.2 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 0.0400 | 0 | -0.0300 | 0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 0.08 | 0.31 | 0.3 | 1.3 | 1.4 |
| Capex / Sales | - | 3% | 48.75% | 25.35% | 50.05% | 41.18% |
| Announcement Date | 5/7/21 | 5/19/22 | 5/10/23 | - | - | - |
1CAD in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.075
GBP
Average target price
0.55
GBP
Spread / Average Target
+633.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.86% | 26.43M | |
| -5.31% | 181B | |
| -1.21% | 108B | |
| -5.53% | 66.57B | |
| +1.22% | 49.95B | |
| +7.03% | 43.84B | |
| +4.91% | 41.71B | |
| +21.96% | 31.59B | |
| +14.45% | 25.3B | |
| -4.81% | 23.83B |
- Stock Market
- Equities
- OBI Stock
- Financials Ondine Biomedical Inc.
